Initial Treatment of Multisystem Inflammatory Disease in Children

Two observational studies leave unanswered questions about the optimal initial treatment for MIS-C.

Shortly after the first descriptions of COVID-19 disease in children, a systemic and multisystem inflammatory condition (MIS-C; sometimes called pediatric inflammatory multisystem syndrome) was described (NEJM JW Pediatr Adolesc Aug 2020 and JAMA 2020; 324:259 and 294). Given the clinical similarities to Kawasaki disease, MIS-C was treated with immunomodulatory agents, including intravenous immunoglobulin (IVIG) and corticosteroids. Two studies have now retrospectively examined the effects of MIS-C treatments.

Son and colleagues analyzed data from 596 patients admitted with MIS-C to 58 U.S. hospitals submitted to a CDC surveillance registry between March and October 2020. Data included cardiovascular outcomes of 518 children who received var…

Reviewing Author

Deborah Lehman, MD

Disclosures

Nothing to disclose

Deborah Lehman, MD

Disclosures

Nothing to disclose

Initial Treatment of Multisystem Inflammatory Disease in Children

Topics

Reviewing Author